On Friday, Shares of Burlington Stores Inc (NYSE:BURL), gained 1.08% to $49.43.
Burlington Stores, declared its results for the third quarter and nine months ended October 31, 2015.
Tom Kingsbury, President and Chief Executive Officer stated, “We are happy with our third quarter results, which comprised a 2.8% improvement in comparable store sales on top of a 5.2% improvement in last year’s third quarter. Adjusted Net Income per Share surpassed our expectations due to sales growth, expansion in gross margin, leverage in SG&A and share repurchase activity. I would like to thank our store and corporate teams for contributing to these results.”
Burlington Stores, Inc. operates as a retailer of branded apparel products in the United States. The company offers fashion-focused merchandise, counting women’s ready-to-wear apparel, menswear, youth apparel, baby products, footwear, accessories, home décor and gifts, and coats.
Shares of Amgen, Inc. (NASDAQ:AMGN), declined -0.26% to $163.52, during its last trading session.
Amgen, declared the submission of a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501, a biosimilar candidate to Humira (adalimumab). Amgen believes this submission is the first adalimumab biosimilar application presented to the FDA and represents Amgen’s first BLA submission using the 351(k) biosimilar pathway.
“The submission of Amgen’s first biosimilar application to the FDA is an exciting milestone, expanding our inflammation portfolio to provide additional therapeutic options to patients,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “Patients with chronic inflammatory conditions are faced with a noteworthy burden of disease requiring long-term treatment. Amgen’s branded biologic medicines and biosimilars are developed and manufactured according to the same high standards, and we are committed to delivering high-quality medicines to patients with serious inflammatory diseases.”
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
Finally, Shares of Gold Fields Limited (ADR) (NYSE:GFI), ended its last trade with -0.82% loss, and closed at $2.42.
Gravitas Financial Inc., declared the formation of a specialized merchant bank, Gravitas International Inc. (“GIC” or the “Corporation”), as part of its strategy to focus on both domestic and international opportunities. GIC is a jointly owned venture between Gravitas and Illium Capital Corp. (“ILLIUM”), a merchant bank focused on cross border capital markets opportunities between China and Canada. Both parties agreed to form GIC to hold certain planned investments and to work together to maximize the value of the Corporation for their mutual benefit. The newly formed Corporation will focus on planned capital market mandates by utilizing various financial distribution channels. It will especially look to capitalize on cross border opportunities between China and Canada as several of its key directors and officers have strong connections in mainland China. Certain aspects of the agreement may require further board, shareholders and regulatory approvals.
Gold Fields Limited operates as a gold mining company. The company engages in the exploration, extraction, processing, and smelting of gold and copper properties. It holds interests in eight operating mines in South Africa, Ghana, Australia, and Peru.